Eledon Pharmaceuticals Financials - Benzinga

Eledon Pharmaceuticals Inc

ELDNNASDAQ

Trade with Public

Trade with Public

$3.70

At close: Aug 14, 5:00 PM EST

$3.60

-0.10-2.7%

After Hours: 7:23 PM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Eledon Pharmaceuticals Financials

Eledon Pharmaceuticals (ELDN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from

Benzinga Newsdesk

PRO
Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from

Benzinga Newsdesk

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.

Vandana Singh

PRO
Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the

Benzinga Newsdesk

PRO
Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28) per share from the

Benzinga Newsdesk

Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results

Avi Kapoor